Ami Fadia
Stock Analyst at Needham
(4.11)
# 581
Out of 4,412 analysts
206
Total ratings
50.24%
Success rate
11.98%
Average return
Main Sectors:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Buy | $97 | $93.00 | +4.30% | 16 | Apr 26, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Hold | n/a | $13.69 | - | 10 | Apr 26, 2024 | |
| BIIB Biogen | Reiterates: Buy | $294 | $208.90 | +40.74% | 25 | Apr 25, 2024 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Buy | $33 | $14.92 | +121.18% | 11 | Apr 25, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Hold | n/a | $135.99 | - | 1 | Apr 23, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $82 → $90 | $73.26 | +22.85% | 17 | Apr 22, 2024 | |
| IMRX Immuneering | Reiterates: Buy | $15 | $1.47 | +920.41% | 6 | Apr 12, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $36 → $46 | $35.96 | +27.92% | 10 | Apr 12, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Buy | $50 | $29.32 | +70.53% | 18 | Apr 11, 2024 | |
| MRUS Merus | Reiterates: Buy | $66 | $45.04 | +46.54% | 15 | Apr 11, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $43 | $22.73 | +89.18% | 10 | Apr 10, 2024 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $22 | $17.81 | +23.53% | 22 | Apr 9, 2024 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Buy | $32 | $16.71 | +91.50% | 3 | Apr 9, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $220 | $109.46 | +100.99% | 16 | Mar 20, 2024 | |
| COGT Cogent Biosciences | Reiterates: Buy | $18 | $6.02 | +199.00% | 12 | Feb 26, 2024 | |
| AMRN Amarin Corporation | Maintains: Outperform | n/a | $0.87 | - | 1 | Feb 1, 2021 | |
| PCRX Pacira BioSciences | Downgrades: Market Perform | n/a | $26.33 | - | 3 | Jan 21, 2021 | |
| ITRM Iterum Therapeutics | Maintains: Market Perform | n/a | $1.67 | - | 3 | Oct 1, 2020 | |
| PRGO Perrigo Company | Maintains: Outperform | n/a | $31.94 | - | 3 | Sep 17, 2020 | |
| TEVA Teva Pharmaceutical | Upgrades: Market Perform | n/a | $13.81 | - | 2 | Oct 1, 2018 | |
| HRTX Heron Therapeutics | Initiates: Outperform | n/a | $2.45 | - | 1 | Jan 3, 2018 | |
| SCPH scPharmaceuticals | Initiates: Outperform | n/a | $4.49 | - | 1 | Dec 12, 2017 |
Blueprint Medicines
Apr 26, 2024
Reiterates: Buy
Price Target: $97
Current: $93.00
Upside: +4.30%
Sage Therapeutics
Apr 26, 2024
Reiterates: Hold
Price Target: n/a
Current: $13.69
Upside: -
Biogen
Apr 25, 2024
Reiterates: Buy
Price Target: $294
Current: $208.90
Upside: +40.74%
Day One Biopharmaceuticals
Apr 25, 2024
Reiterates: Buy
Price Target: $33
Current: $14.92
Upside: +121.18%
Neurocrine Biosciences
Apr 23, 2024
Reiterates: Hold
Price Target: n/a
Current: $135.99
Upside: -
Intra-Cellular Therapies
Apr 22, 2024
Maintains: Buy
Price Target: $82 → $90
Current: $73.26
Upside: +22.85%
Immuneering
Apr 12, 2024
Reiterates: Buy
Price Target: $15
Current: $1.47
Upside: +920.41%
Revolution Medicines
Apr 12, 2024
Maintains: Buy
Price Target: $36 → $46
Current: $35.96
Upside: +27.92%
Harmony Biosciences Holdings
Apr 11, 2024
Reiterates: Buy
Price Target: $50
Current: $29.32
Upside: +70.53%
Merus
Apr 11, 2024
Reiterates: Buy
Price Target: $66
Current: $45.04
Upside: +46.54%
Bicycle Therapeutics
Apr 10, 2024
Reiterates: Buy
Price Target: $43
Current: $22.73
Upside: +89.18%
Avadel Pharmaceuticals
Apr 9, 2024
Reiterates: Buy
Price Target: $22
Current: $17.81
Upside: +23.53%
ACADIA Pharmaceuticals
Apr 9, 2024
Reiterates: Buy
Price Target: $32
Current: $16.71
Upside: +91.50%
Jazz Pharmaceuticals
Mar 20, 2024
Reiterates: Buy
Price Target: $220
Current: $109.46
Upside: +100.99%
Cogent Biosciences
Feb 26, 2024
Reiterates: Buy
Price Target: $18
Current: $6.02
Upside: +199.00%
Amarin Corporation
Feb 1, 2021
Maintains: Outperform
Price Target: n/a
Current: $0.87
Upside: -
Pacira BioSciences
Jan 21, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $26.33
Upside: -
Iterum Therapeutics
Oct 1, 2020
Maintains: Market Perform
Price Target: n/a
Current: $1.67
Upside: -
Perrigo Company
Sep 17, 2020
Maintains: Outperform
Price Target: n/a
Current: $31.94
Upside: -
Teva Pharmaceutical
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $13.81
Upside: -
Heron Therapeutics
Jan 3, 2018
Initiates: Outperform
Price Target: n/a
Current: $2.45
Upside: -
scPharmaceuticals
Dec 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $4.49
Upside: -